Pharmadrug EBIT

The latest EBIT for LMLLF is $-280K as of June 2026. That compares with $-180K in the prior-year period — down 53.0% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Pharmadrug's historical trend and sector peers before judging valuation or financial health.

Over the past year, LMLLF's EBIT moved from $-180K to $-280K — a 53.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pharmadrug's operating scale or balance-sheet position.

Against its sector companies, LMLLF currently prints $-280K for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Pharmadrug's growth, margins, and balance sheet.

A EBIT figure of $-280K for LMLLF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting LMLLF's EBIT ($-280K), review year-over-year change from $-180K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.